Cognitionthe developer of non-invasive brain computer interface (BCI) technology has announced that BlackRock Neurotech, a company that manufactures embedded BCIs, will provide Cognixion’s Axon-R wearable neural interface platform to research institutions through its distribution network.
BlackRock NeuroTech serves as an unlimited distributor of Cognixion’s Axon-R. It is a non-invasive wearable that allows for accurate measurement and regulation of brain activity via visual stimuli, biofeedback, and neurofeedback.
The Axon-R is a research grade device aimed at investigating neuroscience, educational applications and neurosis. Not cleared by the FDA for clinical or therapeutic applications.
In a statement, BlackRock Neurotech said its central focus will remain on the embedded sovereign BCIS that restores speech, movement and sensation. However, it emphasizes that the availability of research-grade tools such as Axon-R opens the door for interdisciplinary innovation.
“This collaboration represents the strong integrity of complementary technologies that have a significant impact on the overall neurotechnical application,” Cognixion CEO Andreas Forsland said in a statement.
“Combined with BlackRock NeuroTech’s implant technology and Cognixion’s AI and augmented reality platform, it opens new doors for both researchers and clinicians, providing transformative solutions for the individuals who ultimately serve them.”
Marcus Gerhardt, CEO of BlackRock NeuroTech, said his company’s mission is to restore capabilities.
“By expanding access to research-grade tools like Axon-R, we aim to have a clinical focus on sovereign, faithful, implantable technologies that restore language, movement and sensation, while supporting early exploration of neural interfaces,” Gerhardt said in a statement.
Bigger trends
In March, Cognixion’s Forsland spoke HIMSS TV uses augmented reality, AI, and brain computer interface technologies to enable traumatic brain injury, stroke and ALS to communicate using eyes.
In 2024, Noldus Information Technology collaborated with BlackRock NeuroTech to integrate Noldus’ Ethovision XT Behavioral Tracking Software with BlackRock’s electrophysiology system to create a unified behavioral and neural research platform.
The integration enables real-time synchronization of Ethovision XT behavioral tracking data using BlackRock EEG recordings in mouse and rats.
The aim was to enable researchers to link real-time neural activities to the outcome of their behavior more accurately and efficiently.
Other companies in the BCI space include those based in New York Synchron announced this week that it will be the first BCI company to reach native integration with Apple’s BCI Human Interface Device (BCI HID) profile.
The company’s technology aims to allow people to use their own ideas to control digital devices such as iPhones, iPads, and Apple Vision Pro.
Earlier this month, Elon Musk Neuralink announced that it had ported the brain computer interface to a man named Brad Smith. BradSmith has ALS, is completely nonverbal and can now communicate using telepathy.
Smith Video released X is about his experience with NeuralInk, narrated using replicas generated by Smith’s voice AI cloned from previous recordings.
In March, Neuralink submitted an application to The US Patent and Trademark Office (USPTO) trademarks the terms “telepathy,” “blindsight,” and “telekinesis.”
The application is related to the provision of Neuralink. telepathy A brain computer interface aimed at enabling users to control devices in their own way. Blind It is an implant intended to restore vision in blind individuals, telekinesis Mask is the term used interchangeably as telepathy, and refers to a control device using one’s own mind.
Neuralink received it last year Approval from Health Canada to conduct clinical trials with N1 brain implants and R1 robots. This is used to place the implant in the brain.
The “Canada’s Precisely Robotally Implanted Brain Computer Interface” (Can Prime) study was conducted by University Health Network Hospital at Toronto Western Hospital.
Can-Prime evaluated the safety of a company’s N1 implant, which was designed to allow individuals to control computers or mobile devices using their mind and company’s R1 surgical robot, which is used to place 64 threads of N1 implants in the patient’s brain.
